|AHFS/Drugs.com||Micromedex Detailed Consumer Information|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||530.661 g·mol−1|
|3D model (JSmol)|
Glycerol phenylbutyrate (USAN), trade name Ravicti, is a medication used in the treatment of certain inborn urea cycle disorders. The medication works by preventing the harmful buildup of ammonia in the body. It is an FDA-approved prescription drug in the US. It is approved for anyone over 2 months of age. It was developed by Hyperion Therapeutics based on the existing drug Buphenyl, and received approval on February 1, 2013. Hyperion has been criticized for setting a high price for the drug. The price was set at US$250,000–290,000. In 2014, the drug generated $30.8 million in net sales, far behind the older and less expensive Buphenyl ($113.6 million in sales). In March 2015, Horizon Pharma acquired Hyperion Therapeutics and thus Raviciti.
- "FDA approves new drug for the chronic management of some urea cycle disorders". U.S. Food and Drug Administration. 1 February 2013. Archived from the original on 2013-03-07. Retrieved 2013-04-01.
- "FDA Approved Drug Products: Ravicti". Drugs@FDA. U.S. Food and Drug Administration. Retrieved 18 February 2018.
- Herder M (April 2016). "Orphan drug incentives in the pharmacogenomic context: policy responses in the USA and Canada". Journal of Law and the Biosciences. 3 (1): 158–166. doi:10.1093/jlb/lsv060. PMC 5033429. PMID 27774236.
- "Horizon Pharma to Acquire Hyperion Therapeutics for $1.1B". Genetic Engineering & Biotechnology News. 30 March 2015.
- "Glycerol phenylbutyrate". Drug Information Portal. U.S. National Library of Medicine.